EUVIMEDEUVIMED entdecken
Crossref

Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor

Hugh N. Nuthall, William Kielbasa, Eric M. Woerly, Jorg Hendle, Paul Goldsmith, Susan L. Dubois, Feiyu Fred Zhang, Kevin B. Donnelly, Adam S. Fleisher, Stephen L. Lowe, Sergey Shcherbinin, Leonard L. Winneroski und 10 weitere

Journal of Medicinal Chemistry · 21.11.2026

DOI: 10.1021/acs.jmedchem.6c02053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.11.2026. Verfasst von Hugh N. Nuthall und 21 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postmortem brain examinations in Alzheimer’s disease (AD) reveal β-amyloid plaques, neurofibrillary tangles resulting from tau protein aggregation, and neuronal and synaptic loss, which collectively impair brain function. O-linked N-acetylglucosami-nidase (OGA) is an enzyme that removes O-linked β-N-acetylglucosamine (O-GlcNAc) from proteins including tau. In animal tauopathy models, OGA inhibition was shown to increase O-GlcNAc−tau levels, leading to reduced tau hyperphosphorylation and aggregation. These results inspired efforts to develop OGA inhibitors for the treatment of AD and tauopathies. Here we report the discovery and clinical development of ceperognastat (LY3372689), a low-dose, CNS-penetrant OGA inhibitor that has been evaluated in a completed phase II study in patients with early symptomatic AD.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Nuthall, H. N., Kielbasa, W., Woerly, E. M., Hendle, J., Goldsmith, P., Dubois, S. L., Zhang, F. F., Donnelly, K. B., Fleisher, A. S., Lowe, S. L., Shcherbinin, S., Winneroski, L. L., Lopez, J. E., Dreyfus, N. J., Evans, D. A., Lindsay-Scott, P. J., Rathmell, R. E., Gilmore, J., Collins, E. C., …, & Mergott, D. J. (2026). Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02053

Vancouver

Nuthall HN, Kielbasa W, Woerly EM, Hendle J, Goldsmith P, Dubois SL, et al. Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02053

BibTeX
@article{Nuthall2026,
  author = {Nuthall, Hugh N. and Kielbasa, William and Woerly, Eric M. and Hendle, Jorg and Goldsmith, Paul and Dubois, Susan L. and Zhang, Feiyu Fred and Donnelly, Kevin B. and Fleisher, Adam S. and Lowe, Stephen L. and Shcherbinin, Sergey and Winneroski, Leonard L. and Lopez, Jose E. and Dreyfus, Nicolas J.-F. and Evans, David A. and Lindsay-Scott, Peter J. and Rathmell, Richard E. and Gilmore, Jeremy and Collins, Emily C. and Mancini, Michele and Hutton, Michael and Mergott, Dustin J.},
  title = {Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02053}
}
Kostenlos starten →